Comparative Pharmacology
Head-to-head clinical analysis: MULTRYS versus RUVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MULTRYS versus RUVITE.
MULTRYS vs RUVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MULTRYS is a multivitamin preparation for intravenous infusion; its components serve as coenzymes or cofactors in various metabolic pathways, including energy production, red blood cell formation, and antioxidant defense.
RUVITE (ruxolitinib) is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2, which mediates signaling of cytokines and growth factors involved in hematopoiesis and immune function.
10 mL (one vial) intravenously three times per week, not to exceed 10 mL per dose.
100 mg orally once daily with or without food.
None Documented
None Documented
Not applicable as a single entity; values vary by component. For example: thiamine 10-20 minutes (plasma), riboflavin 1-2 hours, vitamin B6 2-3 weeks (tissue stores), vitamin C 16 days (10-20 days for depletion), biotin 1-2 days, folic acid 3-4 hours (plasma), vitamin B12 4-5 days (plasma), zinc 2-3 days (plasma), copper 12-24 hours, selenium 11-20 days, chromium 0.5-1 day, manganese 5-10 days.
The terminal elimination half-life is approximately 2-4 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged to 8-12 hours, necessitating dose adjustment.
Renal elimination of individual vitamins and trace elements varies; no intact drug is excreted, as MULTRYS is a mixture. Approximate ranges: thiamine 50% unchanged in urine, riboflavin 60-70% as metabolites in urine, vitamin B6 70-80% as 4-pyridoxic acid in urine, vitamin C 50% unchanged in urine, biotin 50% unchanged in urine, folic acid mainly as metabolites in urine, vitamin B12 via bile (50-60%) and urine (10-30%). Trace elements: zinc primarily fecal (90%), copper primarily fecal (80-90%), selenium primarily urine (50-60%), chromium primarily urine (80%), manganese primarily fecal (95-97%).
Renal excretion of unchanged drug accounts for approximately 30-50% of the administered dose; biliary/fecal elimination accounts for the remainder, with 20-30% recovered in feces as metabolites and parent drug. Total clearance is about 100-150 mL/min.
Category C
Category C
Multivitamin/Mineral Supplement
Multivitamin